New drug combo aims to fight Hard-to-Treat breast cancer recurrence
NCT ID NCT06008275
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether combining two oral drugs, neratinib and ruxolitinib, is safe and can shrink tumors in people with metastatic triple-negative breast cancer that has come back on the chest wall after chemotherapy. About 20 women will take the drugs daily, and doctors will measure how many respond. The goal is to find a new option for this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neratinib and ruxolitinib (oral tablets)
What this could lead to
If it works, this could point toward a new treatment option for people with metastatic triple-negative breast cancer that has returned on the chest wall.
What could go wrong
This is a very early, small trial (20 people) focused on safety and dosing. The combination may not shrink tumors or could cause side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••